OTSP Release: Diabetes Drug ACTOS(R) (pioglitazone HCl) Halted Progression of Key Marker For Atherosclerosis; Improvements Indicated By Carotid Intima-Media Thickness (CIMT)

CHICAGO, IL -- (MARKET WIRE) -- November 13, 2006 -- Researchers today presented data showing that ACTOS® (pioglitazone HCl) halted the progression of atherosclerosis, as indicated by carotid intima-media thickness (CIMT), in patients with type 2 diabetes. Results from the clinical trial CHICAGO (Carotid intima-media tHICkness in Atherosclerosis using pioGlitazOne), were published in an early online issue of the Journal of the American Medical Association.